RE: This will touch 50p minimum this afternoon.3 Mar 2022 10:24
Rare Groove, how is this an excellent RNS?...
Due to the need to modify the study design in light of the emergence of the Omicron variant of SARS-CoV-2, the US National Institutes of Health (NIH) ACTIV-2 trial team has asked Synairgen to temporarily pause activities to prepare clinical supplies for ACTIV-2 Phase 3 until the timeline for the activation of this agent in the trial is clarified. Synairgen continues to await the Phase 2 data from the US NIH ACTIV-2 trial in home-based COVID-19 participants, expected by mid-year.